Resverlogix Corp.

RVX

CA76128M1086

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 08:40:01 07/06/2024 pm IST			5-day change	1st Jan Change
0.05 ^CAD	0.00%		-9.09%	-28.57%

15/05	Resverlogix Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
01/04	Resverlogix Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Ken Lebioda Steps Down as Senior Vice President, Business and Corporate Development of Resverlogix

July 06, 2021 at 03:30 pm IST

Resverlogix Corp. announced that Ken Lebioda is stepping down as Senior Vice President, Business and Corporate Development, effective immediately.

Latest news about Resverlogix Corp.

Resverlogix Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
Resverlogix Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04	CI
Resverlogix Corp. Announces Resignation of Shawn Lu from the Board of Directors	21/02	CI
Resverlogix Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
Resverlogix Corp. Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes	04/23/04	CI
Resverlogix Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	12/23/12	CI
Transcript : Resverlogix Corp. - Shareholder/Analyst Call	20/23/20
Resverlogix Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
Resverlogix Corp. Auditor Raises 'Going Concern' Doubt	31/23/31	CI
Resverlogix Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	31/23/31	CI
Resverlogix Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	12/22/12	CI
Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions	28/22/28	MT
Resverlogix up 4% as Publishes New Data Highlighting Apabetalone's Benefit in Non-alcoholic Fatty Liver Disease	22/22/22	MT
Resverlogix Publishes New Data Highlighting Apabetalone's Benefit in Non-alcoholic Fatty Liver Disease	22/22/22	MT
Resverlogix Brief: Publishing New Data Highlighting Apabetalone's Benefit in Non-alcoholic Fatty Liver Disease	22/22/22	MT
Resverlogix Corp. Announces Management Changes	16/22/16	CI
Resverlogix Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	13/22/13	CI
Resverlogix Corp. Appoints Dicky To as Director	22/22/22	CI
Transcript : Resverlogix Corp. - Shareholder/Analyst Call	22/22/22
Resverlogix Reports Research Highlighting Safety of BD2-selective BET Inhibitors; Shares Fell 12% on Tuesday	08/22/08	MT
Resverlogix Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022	14/22/14	CI
Resverlogix Announces Type C Meeting with FDA For Phase 3 High-Risk COVID-19 Outpatient Study	09/22/09	MT
U.S. Food and Drug Administration Grants Resverlogix Corp. Request for Type C Meeting to Review Clinical Trial Protocol for Phase 3 Study	09/22/09	CI
Resverlogix Brief: Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study	09/22/09	MT
Resverlogix Details One-Year Extension of Debenture	20/22/20	MT

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

Sector

Biotechnology & Medical Research

Calendar

01/08/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
RESVERLOGIX CORP.	-28.57%	9.99M
VERTEX PHARMACEUTICALS INCORPORATED	+18.72%	125B
REGENERON PHARMACEUTICALS, INC.	+14.19%	108B
BIONTECH SE	-4.93%	24.21B
ARGENX SE	+3.23%	22.78B
GENMAB A/S	-10.44%	17.96B
WUXI APPTEC CO., LTD.	-41.74%	16.43B
BEIGENE, LTD.	-13.31%	16.37B
NEUROCRINE BIOSCIENCES, INC.	+2.44%	13.58B
SAREPTA THERAPEUTICS, INC.	+27.89%	11.66B